Paul W. Noble, MD, FCCP

Professor of Medicine
Director, Division of Pulmonary, Allergy, and Critical Care Medicine
Duke University School of Medicine
Durham, North Carolina

Paul W. Noble, MD, FCCP, received his bachelor of arts degree from Haverford College in Pennsylvania, and his medical degree from New York University School of Medicine. He completed his medical residency and chief residency at the University of California, San Francisco Hospitals. He completed his pulmonary and critical care fellowships at the University of Colorado and the National Jewish Center in Denver, Colorado.

From 1992-1997 Dr. Noble was assistant professor at Johns Hopkins School of Medicine, where he established the Interstitial Lung Disease Clinic. He moved to the Yale University School of Medicine in 1997, where he became Professor of Medicine in 2004. He served as director of the ILD Program until 2006, when he moved to Duke University as the Chief of the Division of Pulmonary, Allergy and Critical Care Medicine.

Dr. Noble is a physician scientist with an active research laboratory focused on elucidating the basic mechanisms of lung injury, inflammation, and fibrosis. His research laboratory is funded by the National Institutes of Health. He continues to have an active clinical practice in ILD. Dr. Noble is also involved in industry-sponsored clinical trials evaluating new therapies in IPF. He served as the Co-PI for protocol design for the CAPACITY trial evaluating the efficacy of pirfenidone in the treatment of IPF. He is on the Steering Committee for the INSPIRE trial evaluating the efficacy of interferon-gamma 1b in the treatment of IPF.

Dr. Noble is an elected member of the American Society of Clinical Investigation and the American Association of Physicians. He serves on the editorial boards for the American Journal of Respiratory Cell and Molecular Biology and the American Journal of Respiratory and Critical Care Medicine. Dr. Noble’s research has been published in journals such as Science, Nature Medicine, the Journal of Clinical Investigation, and the New England Journal of Medicine.

Disclosure Statement

The France Foundation relies upon faculty members to provide educational information in a manner that is objective and free from bias. In compliance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Commercial Support, all faculty members are required to disclose any conflicts of interest related to the context of their participation in a CME activity. Faculty members have disclosed the following relationships with commercial interests:

Paul W. Noble, MD, has served as a consultant for Actelion, Boehringer Ingelheim, Chronogen, Gilead, InterMune, and Novartis.